Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
Mayo Clinic |
---|---|
Information provided by: | Mayo Clinic |
ClinicalTrials.gov Identifier: | NCT00851955 |
The investigators hypothesize that the CXCR2 ligands/CXCR2 biological axis plays an important role in promoting angiogenesis in PC; and that the genetic changes and the microenvironment of the tumor regulate the expression of CXCR2 ligands/CXCR2 in PC in order to potentiate their angiogenic phenotype. A corollary of this hypothesis is that the cell surface receptors (CXCR2) and the intracellular signaling pathways that mediate the angiogenic responses induced by ELR+ CXC-chemokines are potential targets for novel therapeutic interventions in PC.
Condition |
---|
Chronic Pancreatitis Pancreatic Cancer |
Study Type: | Observational |
Study Design: | Case-Only, Prospective |
Official Title: | Role of CXCR2 Ligands/CXCR2 Biological Axis in Pancreatic Cancer |
Estimated Enrollment: | 150 |
Study Start Date: | May 2007 |
Groups/Cohorts |
---|
1. Normal pancreas patients
Patients with no documented clinical history of pancreatic diseases supported by at least 1 negative imaging test (EUS, CT scan or MRI).
|
2. Chronic pancreatitis patients
Patients with documented diagnosis of moderate to advanced chronic pancreatitis supported by at least 1 positive imaging test (EUS,CT scan or MRI).
|
3. Pancreatic cancer patients
Patients with documented tissue diagnosis (or clinical suspicion) of Pancreatic Cancer.
|
Ages Eligible for Study: | 18 Years to 90 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | Yes |
Sampling Method: | Probability Sample |
Primary Care
Inclusion Criteria:
Exclusion Criteria:
Contact: Massimo Raimondo, MD | 904-953-2000 | Raimondo.massimo@mayo.edu |
Contact: Verna A. Skinner, CCRP | 904-953-8982 | skinner.verna@mayo.edu |
United States, Florida | |
Mayo Clinic | Recruiting |
Jacksonville, Florida, United States, 32224 | |
Contact: Verna A. Skinner, CCRP 904-953-8982 skinner.verna@mayo.edu |
Principal Investigator: | Massimo Raimondo, MD | Mayo Clinic |
Responsible Party: | ChiRhoClin, Inc. ( ChiRhonClin ) |
Study ID Numbers: | 07-000099 |
Study First Received: | February 25, 2009 |
Last Updated: | February 25, 2009 |
ClinicalTrials.gov Identifier: | NCT00851955 History of Changes |
Health Authority: | United States: Food and Drug Administration; United States: Federal Government |
Digestive System Diseases Digestive System Neoplasms Pancreatic Neoplasms Endocrine System Diseases Pancreatic Diseases |
Gastrointestinal Neoplasms Endocrinopathy Pancreatitis Endocrine Gland Neoplasms Pancreatitis, Chronic |
Neoplasms Digestive System Diseases Neoplasms by Site Digestive System Neoplasms Pancreatic Neoplasms |
Endocrine System Diseases Pancreatic Diseases Pancreatitis Endocrine Gland Neoplasms Pancreatitis, Chronic |